Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer.
- Author:
Lin HUANG
1
;
Juan HE
2
Author Information
1. Department of Urology, Tumor Hospital Affiliated to Guangxi Medical University, Nanning Guangxi 530021, China.
2. Department of Pathology, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi 545005, China.
- Publication Type:Review
- Keywords:
immunotherapy;
programmed cell death factor ligand-1;
prostate cancer;
programmed cell death factor-1
- MeSH:
B7-H1 Antigen/antagonists & inhibitors*;
Humans;
Immune Checkpoint Inhibitors/therapeutic use*;
Immunotherapy;
Male;
Programmed Cell Death 1 Receptor/antagonists & inhibitors*;
Prostatic Neoplasms/drug therapy*;
Signal Transduction
- From:
National Journal of Andrology
2020;26(10):944-948
- CountryChina
- Language:Chinese
-
Abstract:
Prostate cancer (PCa) has become one of the common malignant diseases in elderly men, and its incidence is increasing year by year. Apart from surgery, radiotherapy and chemotherapy, immunotherapy, as with the programmed death receptor-1 (PD-1) or the programmed death ligand-1 (PD-L1) inhibitor, is a most promising new strategy for the treatment of PCa. PD-1 and PD-L1 inhibitors restore the activity of T cells by blocking the PD-1/PD-L1 signaling pathway in tumor cells, reverse the mechanism of tumor immune escape, recover the immune system and directly kill tumor cells. This review focuses on the current progress in the studies of PD-1 and PD-L1 inhibitors in the treatment of PCa.
